Header Logo

Connection

Kathleen Moore to Benzopyrans

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Benzopyrans.
Kathleen Moore
Connection Strength
0.106
Benzopyrans
  1. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93.
    View in: PubMed
    Score: 0.106
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.